Introduction: Outpatient use of diabetes devices, including continuous glucose monitors (CGM), insulin pumps, and automated insulin delivery (AID) is increasing, and guidelines suggest continuation during hospitalization, despite off label use and limited guidance. We conducted an online survey to understand current real world diabetes technology continuation and use in hospital.
Methods: From May-Nov 2023, a survey was distributed via diabetes-related networks and social media. Eligible participants were living with or caring for someone with diabetes who experienced a hospitalization in the prior year and used a CGM and/or insulin pump at that time.
Results: Of 540 responses, 283 were excluded for ineligibility, incompleteness, or duplication. The remaining cohort (N=258) was mostly ≥18 years (92%), female (69%), white (94%), privately insured (62%), and had type 1 diabetes (93%). Hospitalizations occurred in 45 US states, commonly for surgery (32%), glycemia (20%), or infection (12%). A majority used their devices for ≥90% of their stay (fig). Among inpatient AID users (n=133), 74% felt glucoses were well-controlled vs. 49% of those who discontinued AID (n=33) (p=0.005).
Conclusion: Outpatient diabetes technology is commonly used in hospital glucose management, with users reporting more in target glycemic control. Further research should explore hospital implementation and how effectiveness and operational demands compare to traditional methods.
M.S. Hughes: Consultant; Dexcom, Inc. M. Morgan: None. L. Hsu: None. Y. Liu: None. M. Lee: None. S. Hanes: None. V. Fielding-Singh: None. K.K. Hood: Consultant; Cecelia Health, Sanofi. B.A. Buckingham: Advisory Panel; Medtronic. Research Support; Medtronic. Advisory Panel; Arecor. R. Lal: Consultant; Abbott, Adaptyx Biosciences, Biolinq, Capillary Biomedical, Inc., Deep Valley Labs, Gluroo, PhysioLogic Devices, Portal Insulin, Tidepool. Advisory Panel; Lilly Diabetes.
National Institutes of Health (5K12DK122550, 1K23DK122017, T32DK007217, P30DK116074)
